| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w16014 |
| 来源ID | Working Paper 16014 |
| Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? | |
| Mark Trusheim; Murray L. Aitken; Ernst R. Berndt | |
| 发表日期 | 2010-05-20 |
| 出版年 | 2010 |
| 语种 | 英语 |
| 摘要 | Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile. Employing a data base encompassing all 96 biologics and 212 small molecules newly launched in the U.S. between 1998Q1 and 2008Q4, we compare their downstream clinical and commercial characteristics -- therapeutic class concentration, launch delays following approval, Orphan Drug and priority review status, supplemental indications, black box warning and safety record, and pricing and revenue growth during the product life cycle. We conclude that the market dynamics of biologics differ substantially from those of small molecules, although therapeutic class composition plays a major role. |
| 主题 | Microeconomics ; Households and Firms ; Health, Education, and Welfare ; Health ; Industrial Organization ; Industry Studies |
| URL | https://www.nber.org/papers/w16014 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/573688 |
| 推荐引用方式 GB/T 7714 | Mark Trusheim,Murray L. Aitken,Ernst R. Berndt. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. 2010. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w16014.pdf（1358KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
